Dianthus Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

New york and waltham, mass., may 03, 2024 (globe newswire) -- dianthus therapeutics, inc. (“dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on may 1, 2024, to two newly-hired, non-executive employees. the inducement grants were approved by the company's independent compensation committee and were made as material inducements to acceptance of employment with dianthus in accordance with nasdaq listing rule 5635(c)(4).

New york and waltham, mass., april 11, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for dnth103 at the american academy of neurology (aan) annual meeting, taking place april 13-18, 2024 in denver, colorado and virtually.

New york and waltham, mass., april 05, 2024 (globe newswire) -- dianthus therapeutics, inc. (“dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on april 1, 2024, to six newly-hired, non-executive employees. the inducement grants were approved by the company's independent compensation committee and were made as material inducements to acceptance of employment with dianthus in accordance with nasdaq listing rule 5635(c)(4).

Phase 2 magic trial in generalized myasthenia gravis (gmg) initiated in q1'24 with top-line results  anticipated in 2h'25

New york and and waltham, mass., march 07, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth) (“dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on march 2, 2024, to a newly-hired, non-executive employee. the inducement grant was approved by the company's independent compensation committee and was made as a material inducement to acceptance of employment with dianthus in accordance with nasdaq listing rule 5635(c)(4).

Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.

The healthcare sector has more high return generating companies than many other sectors.

Thanks to the easing concerns in the banking sector and the Fed's willingness to pause rate hikes, it's wise to invest in growth stocks like Blue Bird (BLBD), Salesforce (CRM), and Deckers Outdoor (DECK).

The stock price of Magenta Therapeutics Inc (NASDAQ: MGTA) surged by 51.66% in the most recent trading session. This is why.

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

The stock price of Magenta Therapeutics (MGTA) plummeted over 50% intraday today. This is why.

CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cost-saving measures focus on shaving administrative expenses and new research.

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.